Focus: Natera is a publicly traded diagnostics company specializing in cell-free DNA testing for oncology, prenatal screening, and transplant rejection monitoring. With 5,001–10,000 employees and $1.1B in FY 2025 revenue, it operates at significant scale in the precision diagnostics space.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Hot — 265 jobs added in 30d
Net +119 (265 new, 146 removed). Aggressive expansion phase.
Best fit for diagnostics, commercial, and data-science professionals seeking high-growth exposure; caution for those seeking profitable biotech stability.
Help build intelligence for Natera
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Natera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo